MONTREAL, July 20, 2016 /CNW Telbec/ - SNC-Lavalin
(TSX: SNC) announced today that it has been awarded a $12.5 million contract by Medicago to provide
design services for a new production facility in Quebec City, Canada.
The facility will regroup Medicago's head office and consolidate
all its current Canadian operations. The headquarters will house
research and development activities and commercial production in
the city's Espace d'innovation D'Estimauville (Estimauville
innovation park).
With construction expected to begin in the fall of 2016,
SNC-Lavalin will perform preliminary and detailed engineering
services, procurement of equipment critical to the process
fabrication and the complete supply of automation integration
services. Once complete, the 44,000-M², fully automated facility
will house manufacturing, offices, laboratories, a greenhouse, a
pilot plant and support services.
"Our relationship with Medicago dates back to 2008," said
Ian L. Edwards, President,
Infrastructure, SNC-Lavalin. "We are very proud to be part of a
local project that, once complete, will export vaccines to foreign
markets and help Canada meet its
seasonal and pandemic flu vaccine needs."
About SNC-Lavalin
Founded in 1911, SNC-Lavalin is
one of the leading engineering and construction groups in the world
and a major player in the ownership of infrastructure. From offices
in over 50 countries, SNC-Lavalin's employees are proud to build
what matters. Our teams provide Engineering, Procurement and
Construction (EPC) and Engineering, Procurement, Construction and
Management (EPCM) services to clients in a variety of industry
sectors, including oil and gas, mining and metallurgy,
infrastructure and power. SNC-Lavalin can also combine these
services with its financing and operations and maintenance
capabilities to provide complete end-to-end project
solutions.www.snclavalin.com
SOURCE SNC-Lavalin